Nature's Recent Scientific Reports Publication Describes How Apabetalone May Be a Powerful Agent Against HIV-1
December 12 2017 - 7:30AM
YASTEST
CALGARY, Alberta, Dec. 12, 2017
(GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the
"Company") (TSX:RVX) announced today that a recent Nature
Scientific Reports has published a 12 page publication on BET
(bromodomain and extra-terminal) inhibitors; RVX-208 (apabetalone)
and PFI-1 owned by Resverlogix and Pfizer, respectively. The
publication by Lu et al, "BET inhibitors RVX-208 and PFI-1
reactivate HIV-1 from latency", (Scientific Reports 7, Article
number:
16646, https://www.nature.com/articles/s41598-017-16816-1)
demonstrates that both BET inhibitors can reactivate HIV-1 from
latency. Persistent latent reservoirs of HIV-1 in resting
CD4+T cells are the major obstacle in curing HIV-1 infection. Their
conclusion suggests that BET inhibitors, such as apabetalone
(RVX-208), are a group of leading compounds for potentially
unmasking HIV-1 latency to allow for viral eradication.
Mr. Donald McCaffrey, President
and Chief Executive Officer commented, "We are thrilled to learn
that additional third party researchers are once again confirming
the true potential of BET inhibitors such as apabetalone
(RVX-208). As HIV/AIDS has been a decades-long deadly
disease, we would like to extend an open invitation to any
interested parties, that have the resources, to expedite a new
program utilizing either apabetalone or one of our other follow-on
BET inhibitors to test this hypothesis and provide a novel
therapeutic for this terrible disease."
About
Resverlogix
Resverlogix is developing
apabetalone (RVX-208), a first-in-class, small molecule that is a
selective BET (bromodomain and extra-terminal) inhibitor. BET
bromodomain inhibition is an epigenetic mechanism that can regulate
disease-causing genes. Apabetalone is the first and only BET
inhibitor selective for the second bromodomain (BD2) within the BET
protein called BRD4. This selective inhibition of apabetalone on
BD2 produces a specific set of biological effects with potentially
important benefits for patients with high-risk cardiovascular
disease (CVD), diabetes mellitus (DM), chronic kidney disease,
end-stage renal disease treated with hemodialysis,
neurodegenerative disease, Fabry disease, peripheral artery disease
and other orphan diseases, while maintaining a well described
safety profile. Apabetalone is the only selective BET bromodomain
inhibitor in human clinical trials. Apabetalone is currently being
studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients
with type 2 DM and low high-density lipoprotein (HDL), and is
expected to be initiated in a Phase 2a kidney dialysis trial
designed to evaluate biomarker changes and safety parameters in up
to 30 patients with end-stage renal disease treated with
hemodialysis.
Resverlogix common shares trade on the Toronto
Stock Exchange (TSX:RVX).
Follow us on
Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx)
For further information
please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Resverlogix Corp via Globenewswire
Resverlogix (TSX:RVX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Resverlogix (TSX:RVX)
Historical Stock Chart
From Apr 2023 to Apr 2024